Table 1. Patients Sociodemographic and Clinical Characteristics.
| Original Data | Following Multiple Imputation (N = 3,496) | |||
|---|---|---|---|---|
| Patient characteristics | Un-weighted Frequency of Observation | Un-weighted Total | Weighted Percentages with (95% CI) OR Median with (IQR) | Weighted Median with IQR*, OR Percentages with (95% CI) |
| SexϮ No., N, %, (95% CI) | ||||
| Females | 2,320 | 3,496 | 66.4% (63.8–68.9) | 66.4% (63.8–68.9) |
| Males | 1,176 | 3,496 | 33.4% (31.2–36.2) | 33.4% (31.2–36.2) |
| Age, No., N, %, (95% CI) | ||||
| 15–24 years | 391 | 3,494 | 11.2% (9.6–13.0) | 10.6% (9.0–12.2) |
| 25–34 years | 1,492 | 3,494 | 42.7% (40.7–44.8) | 42.4% (40.1–44.6) |
| 35–44 years | 1,053 | 3,494 | 30.1% (28.4–31.9) | 30.7% (28.8–32.6) |
| 45–54 years | 424 | 3,494 | 12.1% (10.8–13.6) | 12.4% (11.0–13.7) |
| >55 years | 134 | 3,494 | 3.8% (3.2–4.6) | 3.9% (3.2–4.6) |
| observations missing data** | 2 | 3,496 | 0.1% | |
| Median Age (years) No., N, median (IQR) | ||||
| Both sexes | 3,494 | 3,494 | 34 (28–40) | 33 (28–40) |
| Females | 2,320 | 2,320 | 31 (26–38) | 30 (25–37) |
| Males | 1,176 | 1,176 | 38 (32–44) | 37 (32–44) |
| Marital No., N, %, (95% CI) | ||||
| Single | 649 | 3,410 | 19.0% (16.2–22.2) | 20.6% (17.2–24.0) |
| Married | 2,172 | 3,410 | 63.7% (60.9–66.4) | 62.2% (59.2–65.2) |
| Divorced/separated | 219 | 3,410 | 6.4% (5.3–7.9) | 6.5% (5.2–7.9) |
| Widowed | 370 | 3,410 | 10.9% (9.4–12.4) | 10.6% (9.3–11.9) |
| observations missing data** | 86 | 3,496 | 2.5% | |
| Employment status No., N, %, (95% CI) | ||||
| Employed | 1,797 | 3,076 | 58.4% (50.5–65.9) | 61.1% (53.4–68.8) |
| Not currently employed | 1,279 | 3,076 | 41.6% (34.1–49.5) | 38.9% (31.2–46.6) |
| observations missing data** | 420 | 3,496 | 12.0% | |
| Educational Status No., N, %, (95% CI) | ||||
| Tertiary | 639 | 3,009 | 21.2% (17.9–25.0) | 22.7% (19.1–26.2) |
| Secondary | 1,173 | 3,009 | 39.0% (34.9–43.3) | 40.3% (36.1–44.4) |
| Primary | 842 | 3,009 | 28.0% (23.3–33.2) | 25.2% (21.5–28.9) |
| No education | 355 | 3,009 | 11.8% (7.7–17.6) | 11.9% (6.3–17.4) |
| observations missing data** | 487 | 3,496 | 13.9% | |
| Clinic sizeϮ No., N, %, (95% CI) | ||||
| Large (≥1,500) | 2,296 | 3,496 | 65.7% (47.9–80.0) | 70.9% (54.5–87.2) |
| Medium (500–1499) | 800 | 3,496 | 22.9% (11.5–40.5) | 18.8% (5.2–32.2) |
| Small (<500 patients) | 400 | 3,496 | 11.4% (4.1–27.9) | 10.4% (0.8–21.6) |
| RegionϮ | ||||
| North Central | 1,200 | 3,496 | 34.3% (20.1–52.1) | 34.3% (20.1–52.1) |
| North East | 399 | 3,496 | 11.4% (4.1–27.8) | 11.4% (4.1–27.8) |
| North West | 500 | 3,496 | 14.3% (5.8–31.1) | 14.3% (5.8–31.1) |
| South East | 399 | 3,496 | 11.4% (4.1–27.8) | 11.4% (4.1–27.8) |
| South-South | 499 | 3,496 | 14.3% (5.8–31.1) | 14.3% (5.8–31.1) |
| South West | 499 | 3,496 | 14.3% (5.8–31.1) | 14.3% (5.8–31.1) |
| Baseline Cd4 count, No., N, %, (95% CI) | ||||
| >350 cells/mm3 | 201 | 2,876 | 7.0% (5.5–8.9) | 7.2% (5.3–9.1) |
| 201–350 cells/mm3 | 872 | 2,876 | 30.3% (27.6–33.2) | 29.6% (26.6–32.6) |
| 101–200 cells/mm3 | 907 | 2,876 | 31.5% (29.3–33.9) | 32.2% (29.9–34.5) |
| < = 100 cells/mm3 | 896 | 2,876 | 31.2% (28.2–34.3) | 31.0% (27.6–34.4) |
| observations missing data** | 620 | 3,496 | 17.7% | |
| Baseline Median CD4 Count No., N, median (IQR) | ||||
| Both sexes | 2,876 | 2,876 | 159 (81–248) | 161 (83–254) |
| Females | 1,891 | 1,891 | 166 (88–260) | 170 (92.7–265.4) |
| Males | 985 | 985 | 141 (68–223) | 143 (69.9–229.5) |
| WHO Clinical Stage No., N, %, (95% CI) | ||||
| Stage I | 845 | 3,264 | 25.9% (21.1–31.3) | 26.0% (20.5–31.4) |
| Stage II | 850 | 3,264 | 26.0% (22.6–29.8) | 27.0% (23.1–31.0) |
| Stage III | 1,323 | 3,264 | 40.5 (34.6–46.7) | 39.0% (32.5–45.4) |
| Stage IV | 246 | 3,264 | 7.5% (5.1–11.0) | 8.1% (4.9–11.2) |
| observations missing data** | 232 | 3,496 | 6.6% | |
| Baseline functional status | ||||
| Asymptomatic | 2,151 | 3,160 | 68.07% (59.6–75.5) | 62.5% (52.9–72.1) |
| Symptomatic | 909 | 3,160 | 28.8% (22.0–36.7) | 33.1 (24.7–41.6) |
| Bedridden | 100 | 3,160 | 3.2% (2.1–4.8) | 4.3% (2.2–6.4) |
| observations missing data** | 336 | 3496 | 9.6% | |
| NRTI Backbone | ||||
| D4T | 739 | 3,242 | 22.8% (16.6–30.5) | 23.1% (15.0–31.2) |
| TDF | 746 | 3,242 | 23.0% (17.5–29.6) | 23.6% (16.9–30.2) |
| AZT | 1,703 | 3,242 | 52.5% (44.6–60.3) | 51.1% (43.4–58.9) |
| Sub-optimal | 54 | 3,242 | 1.7% (0.9–2.9) | 2.1% (1.0–3.4) |
| observations missing data** | 254 | 3,496 | 7.3% | |
| Baseline hemoglobin category No., N, %, (95% CI) | ||||
| Not Anemic | 372 | 1,700 | 21.9% (18–26.3) | 21.4% (16.8–26) |
| Mild Anemia | 686 | 1,700 | 40.4% (37.7–43.0) | 19% (16.8–21.3) |
| Moderate anemia | 437 | 1,700 | 25.7% (22.7–29.0) | 44.1% (40.4–47.9) |
| Severe anemia | 205 | 1,700 | 12.1% (9.6–15.0) | 15.5% (11.2–19.6) |
| observations missing data** | 1796 | 3,496 | 51.5% | |
| Baseline Median hemoglobin No., N, median (IQR) | ||||
| Both sexes | 1,700 | 1,700 | 10.3 (9–12) | 10.5 (8.97–12.09) |
| Females | 1,096 | 1,700 | 10.0 (8.9–11.3) | 10.19 (8.76–11.7) |
| Males | 604 | 1,700 | 11.0 (9.3–13.0) | 11.26 (9.56–13.03) |
| Baseline weight category No., N, %, (95% CI) | ||||
| 60 kg | 1,155 | 3,286 | 35.2% (31.2–39.3) | 36.4% (31.8–41) |
| 45–60 kg | 1,721 | 3,286 | 52.4% (49.4–55.5) | 50.7% (47.5–54) |
| <45kg | 410 | 3,286 | 12.5% (10.5–14.8) | 12.9% (10.2–15.5) |
| observations missing data** | 210 | 3,496 | 6.0% | |
| Baseline Median weight No., N, median (IQR) | ||||
| Both sexes | 3,286 | 3,286 | 56 (49–65) | 56 (49–65) |
| Females | 2,179 | 2,179 | 54 (47–62) | 54 (47–62) |
| Males | 1,107 | 1,107 | 60 (54–68) | 60 (54–68) |
| CTX at ART initiation | ||||
| Yes | 2,766 | 3,365 | 82.2% (74.9–87.7) | 80.1% (72.3–87.8) |
| No | 599 | 3,365 | 17.8% (12.3–25.1) | 19.9% (12.2–27.7) |
| observations missing data** | 131 | 3,496 | 3.7% | |
| Year of ART start Ϯ No., N, %, (95% CI) | ||||
| 2004–2006 | 390 | 3,496 | 11.2% (7.1–12.0) | 11.2 (7.1–12.0) |
| 2007–2009 | 1,970 | 3,496 | 56.4% (51.6–61.0) | 56.4 (51.6–61.0) |
| 2010–2012 | 1,136 | 3,496 | 32.5% (27.5–38.0) | 32.5 (27.5–38.0) |
Abbreviations: CI, confidence interval; IQR, interquartile range; WHO, World Health Organization; Kgs, kilograms; ART, antiretroviral therapy; D4T, stavudine; 3TC, lamivudine; NVP, nevirapine; EFV, efavirenz; AZT, zidovudine; ABC, abacavir; CTX, co-trimoxazole.
**Unweighted sample estimate.
*Median and IQR calculated across 60 imputed datasets.
ϮVariables with complete data.